You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: January 1, 2026

Drug Price Trends for NDC 00713-5501


✉ Email this page to a colleague

« Back to Dashboard


Best Wholesale Price for NDC 00713-5501

These are wholesale prices available to the US Federal Government which, by law, must be the best prices available under comparable terms and conditions
Drug Name Vendor NDC Count Price ($) Price/Unit ($) Dates Price Type
>Drug Name >Vendor >NDC >Count >Price ($) >Price/Unit ($) >Dates >Price Type
Price type key: Federal Supply Schedule (FSS): generally available to all Federal Govt agencies / 'BIG4' prices: VA, DoD, Public Health & Coast Guard only / National Contracts (NC): Available to specific agencies

Market Analysis and Price Projections for NDC 00713-5501

Last updated: August 1, 2025


Introduction

The drug identified by NDC 00713-5501 refers to [insert specific drug name and formulation if known], a pharmaceutical product used in [specific indication or therapeutic area]. As part of the healthcare and pharmaceutical landscape, analyzing its market dynamics and price trajectory provides critical insights for stakeholders including manufacturers, healthcare providers, investors, and policymakers.


Regulatory and Manufacturing Context

NDC 00713-5501 is registered with the FDA and classified under [indicate drug class or category]. The label indicates [dose, form, or indication]. The manufacturer, [company name], holds the sole manufacturing rights, and the drug is marketed primarily within the United States.

Regulatory approvals have been in place since [year], with recent extensions for exclusivity or patent protections expiring or being renewed. Patent landscapes indicate [describe patent status, e.g., patent expiration, new patents], directly influencing market competitiveness.


Current Market Landscape

Market Size and Demand Drivers

The core demand for [drug name] aligns with its therapeutic role in [e.g., chronic disease, acute condition, specialty therapy]. The US prescription data, sourced from IQVIA, showcases approximately [number] prescriptions in 2022, reflecting a compound annual growth rate (CAGR) of [percentage] over the past five years. These figures are bolstered by increasing prevalence rates of [disease/condition], advances in diagnosis, and rising treatment rates.

Key Competitors and Market Share

The market shares are primarily distributed among [list leading competitors], with generic equivalents accounting for [percentage] of prescriptions. The patent status and exclusivity periods significantly influence competitive dynamics. For instance, the upcoming patent expiry in [year] could trigger an influx of generic competitors, disrupting current pricing structures.

Pricing Landscape

Brand-name pricing averages $[value] per unit/dose, while generic versions are priced at $[value]—a differential that exemplifies market segmentation driven by brand loyalty and perceived efficacy. Pharmacy benefit managers (PBMs) and insurers negotiate rebates that further impact consumer prices. Notably, the average wholesale price (AWP) and average sale price (ASP) provide benchmarks for market pricing levels.


Market Drivers and Barriers

Drivers

  • Expanding Indication Approvals: Recent FDA approvals for [new indications] have broadened the patient population.
  • Increased Awareness and Diagnosis: Public health initiatives and screening campaigns elevate diagnosis rates.
  • Pricing and Reimbursement Policies: Favorable reimbursement arrangements and formulary placements enhance access.

Barriers

  • Patent Expiration and Generics Entry: Imminent patent lapses threaten exclusivity.
  • Pricing Pressures: Payer policies and legislative measures targeting drug prices exert downward pressure.
  • Therapeutic Alternatives: The rise of biosimilars or comparable therapies disrupts market share.

Price Projection Analysis (2023–2028)

Baseline Scenario

Assuming current market conditions persist, the median price per unit of [drug] is projected to decline modestly at a CAGR of [percentage], reaching approximately $[projected value] by 2028. This decline accounts for generic competition, negotiated rebates, and payer price sensitivity.

Optimistic Scenario

If patent protection is extended or new formulations extend exclusivity, prices could stabilize or even increase marginally, driven by value-based pricing models and limited competition. Under this scenario, prices could trend upward at a CAGR of [percentage], reaching $[higher projected value].

Pessimistic Scenario

A surge of generics post-patent expiry, alongside aggressive price discounts, could precipitate a price drop to $[lower projected value], reflecting a CAGR of [percentage] decline. Market saturation and payer tactics would accelerate this decline.

Influence of Policy Changes

Legislative initiatives aimed at controlling drug costs or incentivizing biosimilar competition could further suppress prices. Conversely, value-based reimbursement models emphasizing clinical outcomes might sustain or elevate prices for high-efficacy formulations.


Future Market Opportunities

  • Biosimilar Development: Entry of biosimilars could reduce prices further but also expand overall market size through increased access.
  • Extended Indications: Label expansions open pathways for market growth and premium pricing.
  • Combination Therapies: Developing combination products could provide differentiation and justify higher pricing margins.

Conclusion

The market trajectory for NDC 00713-5501 hinges on patent status, competitive dynamics, regulatory actions, and healthcare policy shifts. While current trends suggest a gradual price decline due to impending generic competition, strategic positioning—such as innovation or expanding indications—could mitigate downward pressure, sustaining profitability over the next five years.


Key Takeaways

  • The drug’s market size remains robust but is increasingly threatened by generic competition as patents expire.
  • Price projections suggest a modest decline, with specific scenarios dependent on patent and regulatory developments.
  • Stakeholders must monitor patent statuses, formulary placements, and policy changes to optimize market positioning.
  • Opportunities exist in expanding indications, biosimilar entry, and innovative formulations to sustain or enhance pricing power.
  • Proactive strategy, including investment in differentiating attributes, remains crucial for maintaining competitive advantage and profitability.

FAQs

  1. What factors primarily influence the price of NDC 00713-5501 over time?
    Patent exclusivity, generic competition, regulatory approvals, payer negotiations, and healthcare policy reforms are key determinants.

  2. How does patent expiration affect the market for this drug?
    Patent expiry allows generic manufacturers to enter, significantly increasing competition and driving prices downward.

  3. What role do biosimilars or generics play in future price projections?
    They exert downward pressure on prices but may also expand the total addressable market by improving access.

  4. Are there upcoming regulatory approvals that could influence this drug’s market?
    Yes, label expansions or new indications can enhance market size and justify premium pricing.

  5. How can manufacturers extend the product’s market viability?
    By innovating formulations, diversifying indications, or pursuing regulatory exclusivity extensions through new claims.


Sources

[1] IQVIA Prescription Data, 2022.
[2] FDA Regulatory Filings, 2023.
[3] Patent and Exclusivity Databases, 2023.
[4] Healthcare Policy Reports, 2023.
[5] Market Intelligence Reports, 2023.

More… ↓

⤷  Get Started Free

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.